A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE2

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-19

Study Completion Date

2018-09-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of Cemdisiran in patients with aHUS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Complement Inhibition in aHUS Dialysis Patients

NCT02464891

Atypical Hemolytic Uremic Syndrome

TERMINATED PHASE2

A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH

NCT02352493

Paroxysmal Nocturnal Hemoglobinuria (PNH)

COMPLETED PHASE1/PHASE2

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT02949128

Atypical Hemolytic Uremic Syndrome (aHUS)

COMPLETED PHASE3

A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT01770951

Atypical Hemolytic Uremic Syndrome (aHUS)

COMPLETED

Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment

NCT02614898

Atypical Hemolytic Uremic Syndrome

TERMINATED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atypical Hemolytic Uremic Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cemdisiran

Group Type EXPERIMENTAL

Cemdisiran

Intervention Type DRUG

Subcutaneous (sc) injection of Cemdisiran

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cemdisiran

Subcutaneous (sc) injection of Cemdisiran

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Willing to provide written informed consent and to comply with the study requirements
2. Age 18 years or older
3. Clinical diagnosis of primary aHUS
4. Clinical thrombotic microangiopathy (TMA) activity
5. Women of child-bearing potential must have a negative pregnancy test, cannot be breast feeding, and must be willing to use a highly effective method of contraception
6. Previously vaccinated with meningococcal group ACWY conjugate vaccine and meningococcal group B vaccine or willingness to receive these vaccinations
7. ADAMTS13 \>10% or other proven aHUS-associated mutation

Exclusion Criteria

1. Clinically significant abnormal laboratory results
2. Positive Shiga toxin producing Escherichia coli test at Screening
3. Suspected secondary aHUS, in the opinion of the Investigator (unless there is a documented aHUS-associated genetic mutation)
4. Positive direct Coombs test
5. Patients who have received hemodialysis for \>3 months
6. Bone marrow transplant recipients
7. Organ transplant recipients, except for kidney transplant recipients with primary aHUS (confirmed by known genetic mutation and kidney biopsy)
8. Known history or evidence of systemic lupus erythematosus or antiphospholipid antibody syndrome
9. History of multiple drug allergies or history of allergic reaction to an oligonucleotide or GalNAc
10. Malignancy (except for non-melanoma skin cancers, cervical in-situ carcinoma, breast ductal carcinoma in situ, or stage 1 prostate carcinoma) within the last 5 years
11. Patients with a poor prognosis that is expected to limit their life expectancy to less than 3 months, in the opinion of the Investigator

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No